Logo 1 Logo 2

Clinical Trial Details

Trial ID: L7290
Source ID: NCT00266253
Associated Drug: Gk Activator (2)
Title: A Study of GK Activator (2) in Patients With Type 2 Diabetes Mellitus Treated With a Stable Dose of Metformin
Acronym:
Status: COMPLETED
Study Results: NO
Results:
Conditions: Diabetes Mellitus Type 2
Interventions: DRUG: GK Activator (2)|DRUG: Metformin
Outcome Measures: Primary: HbA1c mean change from baseline compared with placebo., Week 12 | Secondary: Additional parameters of glycemic and lipid control., Week 12|AEs, laboratory parameters., Throughout study|Pharmacokinetic and exposure-response relationship, Throughout study
Sponsor/Collaborators: Sponsor: Hoffmann-La Roche
Gender: ALL
Age: ADULT, OLDER_ADULT
Phases: PHASE2
Enrollment: 220
Study Type: INTERVENTIONAL
Study Designs: Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT
Start Date: 2005-11
Completion Date: 2007-03
Results First Posted:
Last Update Posted: 2016-11-02
Locations: Phoenix, Arizona, 85012, United States|Chula Vista, California, 91910, United States|Los Angeles, California, 90057, United States|Kissimmee, Florida, 34741, United States|Tampa, Florida, 33603, United States|Lawrenceville, Georgia, 30045, United States|Arkansas City, Kansas, 67005, United States|Benzonia, Michigan, 49616, United States|Springfield, Missouri, 65804, United States|Butte, Montana, 59701, United States|Kettering, Ohio, 45429, United States|Tulsa, Oklahoma, 74104, United States|Medford, Oregon, 97504, United States|Morrisville, Pennsylvania, 19067, United States|Philadelphia, Pennsylvania, 19107, United States|Memphis, Tennessee, 38119, United States|Bellevue, Washington, 98004, United States|Federal Way, Washington, 98003, United States|Adelaide, 5000, Australia|Heidelberg, 3081, Australia|Sydney, 2050, Australia|Edmonton, Alberta, T5N 3Y6, Canada|Vancouver, British Columbia, V5Z 1M9, Canada|London, Ontario, NGA 4V2, Canada|Montreal, Quebec, H1T 2M4, Canada|Sherbrooke, Quebec, J1H 4J6, Canada|Bammental, 69245, Germany|Berlin, 10115, Germany|Essen, 45355, Germany|Giessen, 35385, Germany|Görlitz, 02826, Germany|Hamburg, 20249, Germany|Kuenzing, 94550, Germany|Mannheim, 68161, Germany|Nürnberg, 90402, Germany|Tann, 36142, Germany|Alzira, 46600, Spain|Bacarot Alicant, 03114, Spain|Baracaldo, 48903, Spain|Barcelona, 08036, Spain|Dundee, DD1 5LA, United Kingdom|Frome, BA11 1EZ, United Kingdom|Glasgow, G45 9AW, United Kingdom|Liverpool, L9 7AL, United Kingdom|Motherwell, ML1 3JX, United Kingdom|Northwood, HA6 2RN, United Kingdom|Plymouth, PL6 7TH, United Kingdom
URL: https://clinicaltrials.gov/show/NCT00266253

Drug ID Drug Name Type DrugBank ID Targets Category Latest Progress
D089 Metformin small molecule DB00331 Details